User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Classification and controversies in pathology of ependymomas.

Primary tabs

Godfraind, Catherine [UCL]

PURPOSE: Bailey and Cushing established ependymoma as a brain tumour entity in the first brain tumour classification (1926). Diagnosis of ependymomas is not subject to controversy as long as other tumours presenting ependymoma-like features have been ruled out. Grading conversely is a source of debate. Description of histological features establishing diagnosis and grading of ependymomas may help to better understand this controversy. METHODS: Literature has been reviewed using PubMed with the following key words: ependymoma, +/- prognosis, +/- biomaker, +/- grading, +/- immunohistochemistry, +/- proliferative index. RESULTS: Grading controversy arises from elusive WHO features and individual characteristics of ependymomas including tumour location, tumour pattern/variant and variable expression of biomarkers. CONCLUSION: There is a need for a grading scheme with a proven general ability to dissociate grades, and to predict individual clinical evolution. Only then will stratified and targeted therapeutics for ependymal tumours be possible.

Document type Article de périodique (Journal article) – Journal Article, Review
Access type Accès restreint
Publication date 2009
Journal information "Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery" - Vol. 25, no. 10, p. 1185-93 (2009)
Peer reviewed yes
issn 0256-7040
e-issn 1433-0350
Publication status Publié
Affiliation UCL
MESH Subject Neoplasm Staging ; Humans ; Ependymoma - classification - diagnosis - pathology ; Diagnosis, Differential ; Brain Neoplasms - classification - diagnosis - pathology ; Brain - pathology
Links
  1. Agaoglu FY, Ayan I, Dizdar Y, Kebudi R, Gorgun O, Darendeliler E (2005) Ependymal tumors in childhood. Pediatr Blood Cancer 45:298–303
  2. Bennetto L, Foreman N, Harding B, Hayward R, Ironside J, Love S, Ellison D (1998) Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol Appl Neurobiol 24:434–440
  3. Burger PC, Scheithauer BW (2007) Tumors of the central nervous system. ARP, Washington DC
  4. Carter M, Nicholson J, Ross F, Crolla J, Allibone R, Balaji V, Perry R, Walker D, Gilbertson R, Ellison DW (2002) Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 86:929–939
  5. Ernestus RI, Wilcke O, Schroder R (1989) Intracranial ependymomas: prognostic aspects. Neurosurg Rev 12:157–163
  6. Ernestus RI, Wilcke O, Schroder R (1991) Supratentorial ependymomas in childhood: clinicopathological findings and prognosis. Acta Neurochir (Wien) 111:96–102
  7. Ernestus Ralf-Ingo, Schr�der Roland, St�tzer Hartmut, Klug Norfrid, Prognostic relevance of localization and grading in intracranial ependymomas of childhood, 10.1007/bf00261604
  8. Ernestus RI, Schroder R, Stutzer H, Klug N (1997) The clinical and prognostic relevance of grading in intracranial ependymomas. Br J Neurosurg 11:421–428
  9. Fassett DR, Pingree J, Kestle JR (2005) The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg 102:59–64
  10. Figarella-Branger D, Civatte M, Bouvier-Labit C, Gouvernet J, Gambarelli D, Gentet JC, Lena G, Choux M, Pellissier JF (2000) Prognostic factors in intracranial ependymomas in children. J Neurosurg 93:605–613
  11. Friede RL, Pollak A (1978) The cytogenetic basis for classifying ependymomas. J Neuropathol Exp Neurol 37:103–118
  12. Hirose Yuichi, Aldape Kenneth, Bollen Andrew, James C. David, Brat Daniel, Lamborn Kathleen, Berger Mitchel, Feuerstein Burt G., Chromosomal Abnormalities Subdivide Ependymal Tumors into Clinically Relevant Groups, 10.1016/s0002-9440(10)64061-8
  13. Horn B, Heideman R, Geyer R, Pollack I, Packer R, Goldwein J, Tomita T, Schomberg P, Ater J, Luchtman-Jones L, Rivlin K, Lamborn K, Prados M, Bollen A, Berger M, Dahl G, McNeil E, Patterson K, Shaw D, Kubalik M, Russo C (1999) A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol 21:203–211
  14. Ishizawa K., Komori T., Shimada S., Hirose T., Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors, 10.5414/npp27118
  15. Jaing TH, Wang HS, Tsay PK, Tseng CK, Jung SM, Lin KL, Lui TN (2004) Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas. J Neurooncol 68:255–261
  16. Jouvet A, Fauchon F, Liberski P, Saint-Pierre G, Didier-Bazes M, Heitzmann A, Delisle MB, Biassette HA, Vincent S, Mikol J, Streichenberger N, Ahboucha S, Brisson C, Belin MF, Fevre-Montange M (2003) Papillary tumor of the pineal region. Am J Surg Pathol 27:505–512
  17. Kawano N, Yada K, Yagishita S (1989) Clear cell ependymoma. A histological variant with diagnostic implications. Virchows Arch A Pathol Anat Histopathol 415:467–472
  18. Komori T, Scheithauer BW, Anthony DC, Rosenblum MK, McLendon RE, Scott RM, Okazaki H, Kobayashi M (1998) Papillary glioneuronal tumor: a new variant of mixed neuronal-glial neoplasm. Am J Surg Pathol 22:1171–1183
  19. Korshunov A, Golanov A, Timirgaz V (2000) Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci 177:72–82
  20. Korshunov A, Golanov A, Timirgaz V (2002) Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol 58:255–270
  21. Korshunov Andrey, Neben Kai, Wrobel Gunnar, Tews Bjoern, Benner Axel, Hahn Meinhard, Golanov Andrey, Lichter Peter, Gene Expression Patterns in Ependymomas Correlate with Tumor Location, Grade, and Patient Age, 10.1016/s0002-9440(10)63530-4
  22. Korshunov A, Golanov A, Sycheva R, Timirgaz V (2004) The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 100:1230–1237
  23. Kurt E, Zheng PP, Hop WC, van der Weiden M, Bol M, van den Bent MJ, Avezaat CJ, Kros JM (2006) Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer 106:388–395
  24. Lehman NL (2008) Patterns of brain infiltration and secondary structure formation in supra-tentorial ependymal tumors. J Neuropathol Exp Neurol 67:900–910
  25. Lehman NL (2008) Central nervous system tumors with ependymal features: a broadened spectrum of primarily ependymal differentiation? J Neuropathol Exp Neurol 67:177–188
  26. Lellouch-Tubiana A, Boddaert N, Bourgeois M, Fohlen M, Jouvet A, Delalande O, Seidenwurm D, Brunelle F, Sainte-Rose C (2005) Angiocentric neuroepithelial tumor (ANET): a new epilepsy-related clinicopathological entity with distinctive MRI. Brain Pathol 15:281–286
  27. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer (IARC), Lyon
  28. McGuire CS, Sainani KL, Fisher PG (2009) Both location and age predict survival in ependymoma: A SEER study. Pediatr Blood Cancer 52:65–69
  29. Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B, Lichter P (2006) Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 12:2070–2079
  30. Merchant Thomas E, Jenkins Jesse J, Burger Peter C, Sanford Robert A, Sherwood Scot H, Jones-Wallace Dana, Heideman Richard L, Thompson Stephen J, Helton Kathleen J, Kun Larry E, Influence of tumor grade on time to progression after irradiation for localized ependymoma in children, 10.1016/s0360-3016(01)02801-2
  31. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S, Janssen I, Giangaspero F, Forni M, Finocchiaro G, Genitori L, Giordano F, Riccardi R, Schoenmakers EF, Massimino M, Sozzi G (2006) Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 24:5223–5233
  32. Nazar GB, Hoffman HJ, Becker LE, Jenkin D, Humphreys RP, Hendrick EB (1990) Infratentorial ependymomas in childhood: prognostic factors and treatment. J Neurosurg 72:408–417
  33. Perilongo G, Massimino M, Sotti G, Belfontali T, Masiero L, Rigobello L, Garre L, Carli M, Lombardi F, Solero C, Sainati L, Canale V, del Prever AB, Giangaspero F, Andreussi L, Mazza C, Madon E (1997) Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neuro-oncology Group. Med Pediatr Oncol 29:79–85
  34. Port JD, Brat DJ, Burger PC, Pomper MG (2002) Astroblastoma: radiologic-pathologic correlation and distinction from ependymoma. AJNR Am J Neuroradiol 23:243–247
  35. Preusser M, Wolfsberger S, Czech T, Slavc I, Budka H, Hainfellner JA (2005) Surviving expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol 124:543–549
  36. Preusser M, Heinzl H, Gelpi E, Hoftberger R, Fischer I, Pipp I, Milenkovic I, Wohrer A, Popovici F, Wolfsberger S, Hainfellner JA (2008) Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 53:39–47
  37. Ridley L, Rahman R, Brundler MA, Ellison D, Lowe J, Robson K, Prebble E, Luckett I, Gilbertson RJ, Parkes S, Rand V, Coyle B, Grundy RG (2008) Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol 10:675–689
  38. Rousseau E, Ruchoux MM, Scaravilli F, Chapon F, Vinchon M, De Smet C, Godfraind C, Vikkula M (2003) CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol 29:574–583
  39. Rousseau E, Palm T, Scaravilli F, Ruchoux MM, Figarella-Branger D, Salmon I, Ellison D, Lacroix C, Chapon F, Mikol J, Vikkula M, Godfraind C (2007) Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma. Mol Cancer 6:47
  40. Rubinstein LJ (1989) Pathology of tumours of the nervous system. Edward Arnold
  41. Rushing EJ, Yashima K, Brown DF, White CL 3rd, Shay JW, Risser RC, Gazdar AF (1997) Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas. J Neuropathol Exp Neurol 56:1142–1146
  42. Rushing EJ, Brown DF, Hladik CL, Risser RC, Mickey BE, White CL 3rd (1998) Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype. Mod Pathol 11:464–470
  43. Sala F, Talacchi A, Mazza C, Prisco R, Ghimenton C, Bricolo A (1998) Prognostic factors in childhood intracranial ependymomas: the role of age and tumor location. Pediatr Neurosurg 28:135–142
  44. Singh PK, Gutmann DH, Fuller CE, Newsham IF, Perry A (2002) Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas. Mod Pathol 15:526–531
  45. Snuderl M, Chi SN, De Santis SM, Stemmer-Rachamimov AO, Betensky RA, De Girolami U, Kieran MW (2008) Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. J Neuropathol Exp Neurol 67:911–920
  46. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, Magdaleno S, Dalton J, Calabrese C, Board J, Macdonald T, Rutka J, Guha A, Gajjar A, Curran T, Gilbertson RJ (2005) Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8:323–335
  47. Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S, Rushing EJ (2008) The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors. Mod Pathol 21:165–177
  48. Trembath D, Miller CR, Perry A (2008) Gray zones in brain tumor classification: evolving concepts. Adv Anat Pathol 15:287–297
  49. Wang M, Tihan T, Rojiani AM, Bodhireddy SR, Prayson RA, Iacuone JJ, Alles AJ, Donahue DJ, Hessler RB, Kim JH, Haas M, Rosenblum MK, Burger PC (2005) Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol 64:875–881
  50. Wolfsberger S, Fischer I, Hoftberger R, Birner P, Slavc I, Dieckmann K, Czech T, Budka H, Hainfellner J (2004) Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol 28:914–920
  51. Yan X, Cheng X, Liu J, Luo D, He X, Chen F, Qin C, Wang Y (2008) Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma. Clin Invest Med 31:E206–E211
  52. Zamecnik J, Snuderl M, Eckschlager T, Chanova M, Hladikova M, Tichy M, Kodet R (2003) Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod Pathol 16:980–991
  53. Zheng PP, Pang JC, Hui AB, Ng HK (2000) Comparative genomic hybridization detects losses of chromosomes 22 and 16 as the most common recurrent genetic alterations in primary ependymomas. Cancer Genet Cytogenet 122:18–25
Bibliographic reference Godfraind, Catherine. Classification and controversies in pathology of ependymomas.. In: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, Vol. 25, no. 10, p. 1185-93 (2009)
Permanent URL http://hdl.handle.net/2078.1/21435